文献速递肺结节与肺癌

呼吸科医生对非小细胞肺癌精准医学生物标志物检测的态度与角色

Pulmonologists' Attitudes and Role in Precision Medicine Biomarker Testing for Non-Small Cell Lung Cancer.
PubMed 文献 · Chest · 2024-06-19

该研究通过电子问卷随机调查美国胸科医师学会数据库中的执业呼吸科医生,了解其对非小细胞肺癌生物标志物检测的态度与实践。401名受访者中92%为普通呼吸科医生,62%表示会开具生物标志物检测;执业年限较长、病例量较高及参与多学科肿瘤委员会与开具检测相关(P < .05)。多数受访者认为呼吸科主导初始诊断活检(83%),但较少主导分期(45%)、与患者讨论检测(28%)及开具检测(22%)。

要点

  • 62%的受访呼吸科医生表示会开具生物标志物检测。
  • 执业年限长、病例量高及参与多学科肿瘤委员会与开具检测相关(P < .05)。
  • 未开具检测最常见原因为认为肿瘤科负责(84%)、不在执业范围(46%)及知识不足(51%)。

核心结论

  • 呼吸科医生在开具生物标志物检测方面实践存在差异,许多人将这一责任推给肿瘤科。
  • 尽管支气管镜和呼吸科指南对分期有角色要求,许多医生仍不主导该过程。
  • 许多呼吸科医生缺乏高效完成生物标志物检测所需的资源与多学科基础设施。

研究设计与样本

  • 电子问卷研究,共31个条目,聚焦非小细胞肺癌诊断步骤的态度与实践。
  • 问卷随机发放给美国胸科医师学会分析数据库中的执业呼吸科医生样本。
  • 使用χ2检验和多变量逻辑回归模型进行推断统计。
  • 共401名呼吸科医生回复问卷。

主要发现

  • 92%的受访者为普通呼吸科医生。
  • 62%的受访者表示会开具生物标志物检测。
  • 执业年限较长、病例量较高及参与多学科肿瘤委员会与开具生物标志物检测相关(P < .05)。
  • 83%的受访者认为呼吸科对初始诊断活检负主要责任,45%认为对分期负主要责任,28%认为主导与患者讨论生物标志物检测,22%认为主导开具生物标志物检测。
  • 未开具生物标志物检测的最常见原因包括:肿瘤科负责(84%)、不在执业范围(46%)、缺乏必要知识(51%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite advances in precision medicine for non-small cell lung cancer (NSCLC), biomarker testing for these therapies remains frequently underused, delayed, and inequitable. Pulmonologists often play a critical role in the initial diagnostic steps for patients with lung cancer, and previous data show variability in their knowledge and practices regarding biomarker testing. The purpose of this study is to better understand how pulmonologists view their role in lung cancer care. RESEARCH QUESTION: With the increasing importance of biomarker testing and precision medicine, how do pulmonologists view their role in lung cancer care? STUDY DESIGN: An electronic survey consisting of 31 items focused on attitudes and practices regarding diagnostic steps for NSCLC was randomly distributed to a sample of practicing pulmonologists in the American College of Chest Physicians (CHEST) analytics database. Inferential statistics were performed using χ2 tests and multivariable logistic regression models. RESULTS: A total of 401 pulmonologists responded to the survey. Most (92%) were general pulmonologists, and more than one-half (62%) indicated they order biomarker testing. Longer practice tenure, higher case volumes, and participation in a multidisciplinary tumor board were associated with ordering biomarkers (P < .05). Pulmonology was identified to have the leading responsibility for the initial diagnostic biopsy by most respondents (83%) and less often for staging (45%), leading discussions about biomarker testing with patients (28%), and for ordering biomarkers (22%). The most common reasons for not ordering biomarkers included the following: oncology was responsible (84%), it was not within their scope of practice (46%), or lack of the necessary knowledge (51%). INTERPRETATION: This study shows that pulmonologists vary in their practices for ordering biomarkers, and many defer this responsibility to oncology. Despite the role of bronchoscopy and pulmonology societal guidelines for staging, many defer leadership of this process. Many pulmonologists lack the necessary resources and multidisciplinary infrastructure likely required to efficiently accomplish biomarker testing.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Fox AH, Rudzinski MA, Nietert PJ, et al. Pulmonologists' Attitudes and Role in Precision Medicine Biomarker Testing for Non-Small Cell Lung Cancer. Chest. 2024. PMID: 38906460. doi:10.1016/j.chest.2024.06.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。